Clinical Trials

Nuvance Health® serves as a research site for clinical trials that explore promising new ways to detect, diagnose, treat and prevent diseases.
researcher handles test tube with tweezers

Fighting Disease Through Innovation

Joining a clinical trial at Nuvance Health is a way to help make real progress against disease. As a clinical trial site, we test promising new therapies for diagnosing and treating many diseases. Highlights of our program include:

  • Access to new treatments: Nuvance Health provides a local site for national and international clinical trials. Eligible patients may have access to promising therapies without traveling far from home.
  • Experience: The clinical research team leads a high volume of studies each year and has more than 40 years of collective experience. Nuvance Health’s clinical research coordinators are certified through the Association of Clinical Research Professionals.
  • Focus on patients: Researchers at Nuvance Health are knowledgeable, careful and thorough. We follow guidelines to protect patients and offer suitable treatment options.
  • High standards: Our internal and external Institutional Review Boards review all clinical trials in depth to keep patients safe and comfortable.

A Range of Clinical Trials

Nuvance Health participates in all phases of clinical trials, from Phase I to Phase IV. We study new screening, prevention, diagnostic and treatment options for:

  • Cancer
  • Cardiology
  • Dermatology
  • Electrophysiology
  • Emergency medicine
  • Endocrinology
  • Gastroenterology
  • General surgery
  • Infectious disease
  • Internal medicine
  • Interventional cardiology
  • Nephrology
  • Oncology
  • Pediatrics
  • Perinatology
  • Psychiatry
  • Pulmonary
  • Rheumatology
  • Wound care

Joining a Clinical Trial at Nuvance Health

The care team talks with you about any clinical trials for which you may be eligible. We explain what to expect from a clinical trial, so you can decide if taking part in one is right for you. 


To inquire if you're eligible for a clinical trial, contact: or call (203) 739-4551.

Clinical Trial Listings

  • Arrhythmia 

    Product Surveillance Registry Platform
    Evaluate the periodic reporting of safety and effectiveness of Medtronic market-released products for their intended use.
    Principal Investigator: Sankar Varanasi, MD

    Librexia AF

    A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation.
    Principal Investigators: M. Zubair Jafar, MD / Carol Gemayel-Barra, MD

    Real AF
    Real-world Experience of Catheter Ablation for the Treatment of Symptomatic ParoxysmaL and Persistent Atrial Fibrillation Using Novel CARTO Technologies
    Principal Investigator: David Steckman, MD

  • Asthma
    A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States
    Principal Investigator: Douglas Kahn, MD
  • COPD
    A phase III, 52-week, multinational, multicenter, randomized, double-blind, 2-arm parallel group study comparing efficacy, safety and tolerability of the fixed dose triple combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide (CHF 5993) with the fixed dose dual combination of beclomethasone dipropionate plus formoterol fumarate (CHF 1535), both administered via pMDI in subjects with chronic obstructive pulmonary disease (COPD).
    Principal Investigator: John Chronakos, MD
  • Coronary Disease 

    Study using the Venclose™ System and Venclose MAVEN™ System for Treatment of Chronic Venous Insufficiency of the Great and Small Saphenous Veins and Incompetent Perforator Veins
    Principal Investigator: Louis Kantaros, MD

  • COVID-19
    Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalized adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicenter, randomized, double-blinded, placebo-controlled, parallel-group phase III trial.
    Principal Investigator: Paul Nee, MD
  • Emphysema
    A phase 2, double-blind, randomized, active-control, parallel group study to assess the pharmacokinetics, pharmacodynamics, immunogenicity, and safety of INBRX-101 compared to plasma derived Alpha1-proteinase inhibitor (A1PI) augmentation therapy in adults with Alpha-1 Antitrypsin deficiency (AATD) Emphysema.
    Principal Investigator: Douglas Kahn, MD
  • Eosinophilic Esophagitis 

    SP-1011-004 EAP
    APT-1011 (Fluticasone ODT) Expanded Access Protocol for Patients with Eosinophilic Esophagitis
    Principal Investigator: Mae Tighe, MD

  • Heart Failure  

    Algorithm using LINQ Sensors for Evaluation and Treatment of Heart Failure (ALLEVIATE-HF)

    Principal Investigator: Sankar Varanasi, MD



    This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
    Principal Investigator: James Lyons, MD


    The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the Carillon Mitral Contour System in treating heart failure with functional regurgitation (FMR).
    Principal Investigator: Rajeev Narayan, MD


    Drain HF
    Diuretics Alone vs Aortix Endovascular Device for Acute Heart Failure
    Principal Investigators: James Lyons, MD / Rajeev Narayan, MD

    AIM HIGHer
    Assessment of Implantable CCM in the Heart Failure Group with Higher Ejection Fraction- Heart Failure
    Principal Investigator: James Lyons, MD

  • Infectious Disease

    Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children
    Principal Investigators: Valerie Cluzet, MD / Paul Nee, MD / Paolo Pino, DO

  • Lupus 

    A Prospective Observational Registry of Patients Treated with LUPKYNIS (voclosporin) in the US
    Principal Investigator: Alla Rudinskaya, MD

  • Migraine
    A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport® for the Prevention of Chronic Migraine in Adult Participants
    Principal Investigator: Hida Nierenburg, MD

    A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport® for the Prevention of Episodic Migraine in Adult Participants
    Principal Investigator: Hida Nierenburg, MD
  • Parkinson's Disease 
    A Dose-Blinded Extension Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of UCB0599 in Study Participants with Parkinson's Disease
    Principal Investigator: Robert Bonwetsch, MD
  • Pharmacy
    MMS-22MK-001 (PharmacyKeeper)
    Study to Assess the Impact of the PharmacyKeeperTM Suite of Solutions on Sterile Compounding Safety, Efficiency, and Compliance
    Principal Investigator: Samuel Strong, MD 
  • Radiology
    A Prospective Multicenter Single-Arm Staged Study to Evaluate the Safety and Effectiveness of EmbraceTM Hydrogel Embolic For Transcatheter Embolization of Arterial Bleeding in Solid Organs and Peripheral Arteries
    Principal Investigator: Eric Reiner, MD
  • Stroke 

    Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (ASPIRE)
    Principal Investigator: Paul Wright, MD


    Oceanic Stroke
    A multicenter, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor Asundexian (BAY 2433334) for the secondary prevention of ischemic stroke in adult patients with an acute non-cardioembolic ischemic stroke or high-risk TIA 
    Principal Investigator: Paul Wright, MD


    A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy.

    Principal Investigator: Paul Wright, MD

  • Surgery 

    Registry of Myriad Utilization in Soft Tissue Reconstruction Procedures
    Principal Investigators: John Choi, MD / Pranat Kumar, MD

  • Ulcerative Colitis
    A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis.
    Principal Investigator: Adam Gorelick, MD

    A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily{ as a maintenance therapy in subjects with moderately to severely active ulcerative colitis.

    Principal Investigator: Adam Gorelick, MD